Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Manel Mata-Cases, Josep Franch-Nadal, Emilio Ortega, Jordi Real, Mònica Gratacòs, Bogdan Vlacho & Dídac Mauricio. (2019) Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area. Current Medical Research and Opinion 35:10, pages 1735-1744.
Read now
Read now
Daisuke Yabe, Hitoshi Kuwata, Ryota Usui, Takeshi Kurose & Yutaka Seino. (2015) Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points. Current Medical Research and Opinion 31:7, pages 1267-1270.
Read now
Read now
Articles from other publishers (11)
Ryuichiro Hosoya, Reiko Ishii-Nozawa, Kota Kurosaki & Yoshihiro Uesawa. (2021) Analysis of Factors Associated with Hiccups Using the FAERS Database. Pharmaceuticals 15:1, pages 27.
Crossref
Crossref
Stefano Del Prato, Juan Pablo Frias, Lawrence Blonde, Vanita R. Aroda, Niam Shehadeh, Aramesh Saremi, Terry Dex, Elisabeth Niemoeller, Elisabeth Souhami, Minzhi Liu & Julio Rosenstock. (2020)
Impact of disease duration and β‐cell reserve on the efficacy of switching to
iGlarLixi
in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the
LixiLan‐G
trial
. Diabetes, Obesity and Metabolism 22:9, pages 1567-1576.
Crossref
Crossref
Shirakawa M, Kanamoto Y, Nagaoka H, Honda H & Bando H. (2019) Diabetic cases controlled with low carbohydrate diet (LCD) and GLP-1 receptor agonist (GLP-1 RA). Asploro Journal of Biomedical and Clinical Case Reports 2:S1, pages 38-46.
Crossref
Crossref
Azusa Ohbatake, Kunimasa Yagi, Shigehiro Karashima, Yuki Shima, Yukiko Miyamoto, Hiroyuki Asaka, Satoko Okazaki, Mitsuhiro Kometani, Masa-aki Kawashiri, Yoshiyu Takeda, Takashi Yoneda & Daisuke Chujo. (2019) C-Peptide Area Under the Curve at Glucagon Stimulation Test Predicts Glucose Improvements by GLP-1 Receptor Analogue: A Retrospective Observational Study. Diabetes Therapy 10:2, pages 673-681.
Crossref
Crossref
Ryota Usui, Yui Sakuramachi, Yusuke Seino, Kenta Murotani, Hitoshi Kuwata, Hisato Tatsuoka, Yoshiyuki Hamamoto, Takeshi Kurose, Yutaka Seino & Daisuke Yabe. (2018) Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β-cell function and the achievement of the glycated hemoglobin target 1 year after initiation. Journal of Diabetes Investigation 9:4, pages 822-830.
Crossref
Crossref
Daisuke Yabe & Yutaka Seino. (2017) Cardiovascular safety trials of incretin-based drugs: What do they mean?. Journal of Diabetes Investigation 8:3, pages 272-276.
Crossref
Crossref
Daisuke Yabe, Anu Ambos, Bertrand Cariou, Lea Duvnjak, Marc Evans, Guillermo González-Gálvez, Jay Lin, Elena V. Nikonova, Pedro de Pablos-Velasco, Jean-François Yale & Bo Ahrén. (2016) Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials. Journal of Diabetes and its Complications 30:7, pages 1385-1392.
Crossref
Crossref
Hitoshi Kuwata, Masahiro Iwasaki, Shinobu Shimizu, Kohtaro Minami, Haruyo Maeda, Susumu Seino, Koji Nakada, Chihiro Nosaka, Kenta Murotani, Takeshi Kurose, Yutaka Seino & Daisuke Yabe. (2015) Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial. Diabetologia 59:3, pages 453-461.
Crossref
Crossref
Jennifer J. Macdonald, Shristi Neupane & Roma Y. Gianchandani. (2015) The potential role of incretin therapy in the hospital setting. Clinical Diabetes and Endocrinology 1:1.
Crossref
Crossref
Ryota Usui, Daisuke Yabe, Hitoshi Kuwata, Kenta Murotani, Takeshi Kurose & Yutaka Seino. (2015) Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β-cell function and achievement of HbA1c target one year after initiation. Journal of Diabetes and its Complications 29:8, pages 1203-1210.
Crossref
Crossref
Daisuke Yabe, Akira Kuroe, Koin Watanabe, Masahiro Iwasaki, Akihiro Hamasaki, Yoshiyuki Hamamoto, Norio Harada, Shunsuke Yamane, Soushou Lee, Kenta Murotani, Carolyn F. Deacon, Jens J. Holst, Tsutomu Hirano, Nobuya Inagaki, Takeshi Kurose & Yutaka Seino. (2015) Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients. Journal of Diabetes and its Complications 29:3, pages 413-421.
Crossref
Crossref